Alacevich, Caterina
Thalmann, Inna
Nicodemo, Catia
de Lusignan, Simon
Petrou, Stavros
Funding for this research was provided by:
Higher Education Innovation Fund and ESRC Impact Acceleration Account
Economic and Social Research Council (ES/T008415/1)
National Institute for Health Research Applied Research Collaboration Oxford and Thames Valley at Oxford Health NHS Foundation Trust
National Institute for Health Research (NF-SI-0616-10103)
Article History
Received: 19 June 2022
Accepted: 16 April 2023
First Online: 22 May 2023
Competing interests
: The authors declare no competing interests. SdeL has received funding through his University for vaccine related research from AstraZeneca, GSK, Sanofi, Seqirus, MSD and Takeda. He has been a member of advisory boards for AstraZeneca, Sanofi and Seqirus.